Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences:
-
8th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Participating on Monday, August 14, 2023
-
Sidoti Virtual Micro Cap Conference
Presenting on Wednesday, August 16, 2023 at 12:15 p.m. Eastern Time
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801461002/en/
Contacts
Investors:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
